A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Bevacizumab as Treatment for Patients With Relapsed/Refractory Multiple Myeloma

This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.

Inclusion Criteria:

• Adult patients, 19-75 years of age
• Multiple myeloma.
• Progressive disease after at least 2 lines of prior therapy.

Exclusion Criteria:

• Non-secretory myeloma.
• History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer in situ of the cervix within the last 5 years.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start.
• Clinically significant cardiac disease.